“spinal-muscular-atrophy” Archives

in
Entry Author Date Location
After AGTC Deal Flops, Biogen Bets $800M on Gene Therapy Rival Nightstar 03/04/19 Boston
Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy 02/25/19 National
Passage Bio Gets $116M As Wilson, Yamada Team Up On Gene Therapy Again 02/14/19 National
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More 02/01/19 National
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy 01/31/19 New York
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
Bio Roundup: ASH Wrap, CRISPR Baby Fallout, Moderna’s Record IPO 12/07/18 National
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel 11/09/18 National
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More 10/26/18 National
With $90M Round, Stoke Eyes a “Spinraza For Epilepsy” And a 2019 IPO 10/23/18 Boston
Novartis Buys Endocyte for $2.1B, Making a Second Bet on Radiotherapy 10/18/18 Indiana
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More 10/12/18 National
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More 10/05/18 National
LogicBio Jumps on the Gene Therapy 2.0 Wave and Lines Up an IPO 09/26/18 Boston
Bio Roundup: CRISPR Tests, Parkinson’s Questions, Opioid Bills & More 04/27/18 National
SMA Day: AveXis Gene Therapy Creeps Forward as Biogen Drug’s Sales Slow 04/25/18 Boston
Biogen Pays $1B to Broaden Ionis Pact, Betting More on RNA Drugs 04/20/18 Boston
Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts 04/13/18 National
Novartis Bets $8.7B on AveXis’s Gene Therapy for Spine Disease 04/09/18 National
After Paper Shakes Sector, Gene Therapy Leader Jim Wilson Talks Safety 01/30/18 National
Solid Discloses Duchenne Problems in IPO & Raises Rival’s Hackles 01/25/18 Boston
Disney, Family Offices Back Second Bio Startup from Tech Entrepreneur Haney 01/23/18 Boston
Spark CEO Marrazzo on Gene Therapy Pricing & Paving the Way for the Field 01/12/18 National
Notes From the JPM ’18 Vortex: Gene Therapy’s Reckoning and Lonely Cabs 01/11/18 National
15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) 12/04/17 National
Alnylam Data Puts a Nobel Discovery One Step Closer to Approved Drug 09/20/17 Boston
Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps 07/28/17 National
Biogen, Opening Bottlenecks, Sees Spine Drug Sales, Shares Rise 07/25/17 Boston
Bio Roundup: Trumpcare Is Mean, SCOTUS Says Go, Merck’s Myeloma No 06/16/17 National
Will New Data Open “Bottlenecks” For Biogen’s Pricey Spine Drug? 04/26/17 Boston
Page 2 of 4 « previous page · next page »